Are Symptomatic Endpoints Acceptable in Venous Thromboprophylactic Studies?

Publisher： Karger

E-ISSN： 1424-8840|28|3|109-112

ISSN： 1424-8832

Source： Pathophysiology of Haemostasis and Thrombosis, Vol.28, Iss.3, 2004-11, pp. : 109-112

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Symptomatic Endpoints for Venous Thromboembolism Treatment

By  

Pathophysiology of Haemostasis and Thrombosis, Vol. 28, Iss. 3, 2004-11 ,pp. : 120-126

Karger

Access to resources Recommend Favorite

Which Endpoints to Use in Clinical Trials in Venous Thromboembolism?

By  

Pathophysiology of Haemostasis and Thrombosis, Vol. 28, Iss. 3, 2004-11 ,pp. : 108-108

Karger

Access to resources Recommend Favorite

Selection of Endpoints in Atrial Fibrillation Studies

By  

JOURNAL OF CARDIOVASCULAR ELECTROPHYSIOLOGY, Vol. 13, Iss. S1, 2002-01 ,pp. : S47-S52

John Wiley & Sons Inc

Access to resources Recommend Favorite

Use of Prestudy Heparin Did Not Influence the Efficacy and Safety of Rivaroxaban in Patients Treated for Symptomatic Venous Thromboem‐bolism in the EINSTEIN DVT and EINSTEIN PE Studies

By  

ACADEMIC EMERGENCY MEDICINE, Vol. 22, Iss. 2, 2015-02 ,pp. : 142-149

John Wiley & Sons Inc

Access to resources Recommend Favorite

Surrogate Endpoints for the Assessment of Efficacy in Venous Thromboembolism Treatment Trials

By  

Pathophysiology of Haemostasis and Thrombosis, Vol. 28, Iss. 3, 2004-11 ,pp. : 127-130

Karger

Access to resources Recommend Favorite